AsCNP/JSNP/JSCNP 2019

セッション情報

[AsCNP] ポスター発表

AsCNP » [AsCNP] ポスター発表

[AsCNP_P8] ポスター8
Depression 2

2019年10月12日(土) 16:40 〜 18:10 ポスター会場 (多目的ホール)

Chair: ‌Kazuhiro TAKUMA (Department of Pharmacology, Graduate School of Dentistry, Osaka University, Japan)

16:40 〜 16:45

Shuichi UEDA1, Yasushi KAWAMATA2, Ayuka EHARA1, Tsuyoshi YAMAGUCHI1, Yoshiteru SEO3, Kazutaka SHIMODA2 (1. Department of Histology and Neurobiology, Dokkyo Medical University School of Medicine, Tochigi, Japan, 2. Department of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Tochigi, Japan, 3. Department of Regulatory Physiology, Dokkyo Medical University School of Medicine, Tochigi, Japan)

16:45 〜 16:50

Hiroko IKEDA1, Aimi YAMAGISHI1, Naomi YONEMOCHI1, Takatsune SHIMIZU2, Akihiro MUTO2, Junzo KAMEI3 (1. Department of Pathophysiology and Therapeutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan, 2. Department of Pathophysiology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan, 3. Department of Biomolecular Pharmacology, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Tokyo, Japan)

17:00 〜 17:05

Shuhei KAYASHIMA1, 2, Hiroshi KUNIISHI1, Kazumi YOSHIZAWA2, Masayuki SEKIGUCHI3, Mitsuhiko YAMADA1 (1. Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan, 2. Laboratory of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan, 3. Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan)

17:05 〜 17:10

Mikio YOSHIDA1, Sho HASEGAWA1, Mizuki UCHIDA1, Yoji UCHIDA1, Akihiro MOURI2, 6, Akira YOSHIMI1, 3, Masayoshi MISHINA4, Norio OZAKI3, Toshitaka NABESHIMA5, 6, Yukihiro NODA1, 3, 6 (1. Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, Nagoya, Japan, 2. Department of Regulatory Science for Evaluation and Development of Pharmaceuticals and Devices, Graduate School of Health Sciences, Fujita Health University, Aichi, Japan, 3. Department of Psychiatry, Graduate School of Medicine, Nagoya University, Nagoya, Japan, 4. Brain Science Laboratory, The Research Organization of Science and Technology, Ritsumeikan University, Shiga, Japan, 5. Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences, Aichi, Japan, 6. Japanese Drug Organization of Appropriate Use and Research, Nagoya, Japan )

17:10 〜 17:15

Kazuki TOKORO1, Kyosuke UNO1, 2, Shin-ichi MURAMATSU3, 4, Atsumi NITTA1 (1. Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan., 2. Laboratory of molecular pharmacology faculty of pharmaceutical science, University of Setsunan, Osaka, Japan, 3. Division of Neurology, Department of Medicine, Jichi Medical University, Shimotsuke, JAPAN, 4. Center for Gene and Cell Therapy, Institute of Medical Science, The University of Tokyo, Tokyo, JAPAN)